NO20082376L - Farmasoytiske sammensetninger - Google Patents

Farmasoytiske sammensetninger

Info

Publication number
NO20082376L
NO20082376L NO20082376A NO20082376A NO20082376L NO 20082376 L NO20082376 L NO 20082376L NO 20082376 A NO20082376 A NO 20082376A NO 20082376 A NO20082376 A NO 20082376A NO 20082376 L NO20082376 L NO 20082376L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
compositions
intranasally
methotrexate
inhalation
Prior art date
Application number
NO20082376A
Other languages
English (en)
Norwegian (no)
Inventor
Andrew John Mcglashan Richards
David Middlemiss
Peter Strong
Ann Gail Hayes
David Alexander Vodden Morton
Original Assignee
Vectura Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectura Group Plc filed Critical Vectura Group Plc
Publication of NO20082376L publication Critical patent/NO20082376L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20082376A 2005-11-18 2008-05-26 Farmasoytiske sammensetninger NO20082376L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0523576.7A GB0523576D0 (en) 2005-11-18 2005-11-18 Drug composition and its use in therapy
PCT/GB2006/050397 WO2007057714A2 (en) 2005-11-18 2006-11-17 Pharmaceutical compositions comprising methotrexate

Publications (1)

Publication Number Publication Date
NO20082376L true NO20082376L (no) 2008-08-18

Family

ID=35580338

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082376A NO20082376L (no) 2005-11-18 2008-05-26 Farmasoytiske sammensetninger

Country Status (8)

Country Link
US (1) US20100040691A1 (ja)
EP (1) EP1951245A2 (ja)
JP (1) JP2009515941A (ja)
CN (1) CN101378760A (ja)
CA (1) CA2629437A1 (ja)
GB (1) GB0523576D0 (ja)
NO (1) NO20082376L (ja)
WO (1) WO2007057714A2 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
EP3184099A1 (en) 2009-03-26 2017-06-28 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
CN101926996B (zh) * 2010-08-13 2013-02-13 中南大学 甲氨喋呤和abc抑制剂在制备治疗银屑病药物中的用途
US9061352B2 (en) * 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
WO2012044736A1 (en) * 2010-09-29 2012-04-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
AU2012290123A1 (en) * 2011-08-02 2013-05-02 Antares Pharma, Inc. Subcutaneous needle assisted jet injection administration of methotrexate
CA2846824C (en) 2011-09-14 2021-03-16 Shionogi & Co., Ltd. Pharmaceutical composition for inhalation
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US8545878B1 (en) 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
WO2018163085A1 (en) * 2017-03-07 2018-09-13 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
WO2023247952A1 (en) * 2022-06-21 2023-12-28 Hovione Scientia Limited Crystalline pharmaceutical composition for inhalation comprising sugar and lipid composite particles and process for manufacture

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166149A (en) * 1989-09-08 1992-11-24 Chemex Pharmaceuticals, Inc. Methotrexate compositions and methods of treatment using same
JP2001511134A (ja) * 1997-01-24 2001-08-07 オートイミューン インク メトトレキサートと組合せる耐性化を用いる自己免疫疾患の治療
ID26665A (id) * 1998-01-23 2001-01-25 Novartis Ag Antagonis vla-4
BR0114978A (pt) * 2000-10-26 2004-04-20 Tularik Inc Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
JP2002370985A (ja) * 2001-06-14 2002-12-24 Chugai Pharmaceut Co Ltd 喘息治療剤
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions

Also Published As

Publication number Publication date
JP2009515941A (ja) 2009-04-16
EP1951245A2 (en) 2008-08-06
WO2007057714A2 (en) 2007-05-24
CN101378760A (zh) 2009-03-04
US20100040691A1 (en) 2010-02-18
GB0523576D0 (en) 2005-12-28
CA2629437A1 (en) 2007-05-24
WO2007057714A3 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
NO20082376L (no) Farmasoytiske sammensetninger
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20082097L (no) Farmasoytiske sammensetninger
IL188050A (en) The history of azaindazole, their medicinal preparations and their uses
WO2008127364A3 (en) Antiviral compounds and use thereof
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20081479L (no) 7-(2-Amino-1-hydroksyetyl)-4-hydroksybenzotiazol-2(3H)-ondenvater som beta2-adrenoceptoragonister
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
NO20092254L (no) Pulverformuleringer for valganciclovir
DK1965809T3 (da) Præparater til forbedring af sundhedstilstanden i dyrs tarmsystem og dyrs ydeevne omfattende Beta-glucanerne og Alfa-fucaner
EA201070689A1 (ru) Композиция для личного ухода
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
DK2041069T3 (da) Benzylaminer, fremgangsmåde til fremstilling deraf og deres anvendelse som anti-inflammatoriske midler
ITMI20060158U1 (it) Apparecchiatura per la somministrazione di ossigeno o di aria addizionata da ossigeno,per terapie respiratorie.
BRPI0619911A2 (pt) composto, pró-droga, agente farmacêutico, e, uso do composto
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application